Effect of terazosin on the lipid profile in patients with symptomatic benign prostatic hyperplasia

Urologia Internationalis

Volumn 67, Issue 2, 2001, Pages 156-159

  Akbay, Erdem ^a   Bozlu, Murat ^a   Doruk, Erdal ^a   Akbay, Esen ^a   Çayan, Selahittin ^a   Ulusoy, Ercüment ^a  

^a MERSIN UNIVERSITY   (Turkey)

Author keywords

Benign prostatic hyperplasia; Cholesterol; Lipid; Terazosin

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN; TERAZOSIN; TRIACYLGLYCEROL;

ADULT; AGED; AGING; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DYSLIPIDEMIA; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; SYMPTOMATOLOGY;

ADRENERGIC ALPHA-ANTAGONISTS; ADULT; AGED; CHOLESTEROL; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED; PRAZOSIN; PROSTATIC HYPERPLASIA; TRIGLYCERIDES;

EID: 0034894953     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000050973     Document Type: Article

References (13)

1. A multicenter, hospital study of the efficacy and safety of terazosin and its effects on the plasma cholesterol
2. Alpha 1-blockade for the treatment of hypertension: A megastudy of terazosin in 2214 clinical practice settings
3. Effect of terazosin on serum lipids
4. Antihypertensive therapy: Taking lipids into consideration
5. Evaluation of serum lipid levels in clinical benign prostatic hyperplasia patients with terazosin monotherapy
6. Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: A combined analysis
7. Role of alpha-adrenergic blockers in the treatment of benign prostatic hyperplasia
8. Lipoprotein-cholesterol distributions in selected North American populations: The Lipid Research Clinics Program Prevalence Study
9. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults
10. Alpha-1-adrenergic blockade and lipoprotein metabolism in essential hypertension
11. Metabolic changes during antihypertensive therapies
12. Alpha-adrenergic blockers: Mechanism of action, blood pressure control, and effects of lipoprotein metabolism